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Introduction: Parasitic diseases are a major global problem causing long-term
10disability and death, with severe medical and psychological consequences
around the world. Despite the prevalence of parasitic disease, the treatment
options for many of these illnesses are still inadequate and there is a dire
need for new antiparasitic drugs. In silico screening techniques, which are
powerful strategies for hit generation, are widely being applied in the design
15of new ligands for parasitic diseases.
Areas covered: This article analyses the application of ligand- and structure-
based virtual screening strategies against a variety of parasitic diseases and
discusses the benefits of the integration between computational and experi-
mental approaches toward the discovery of new antiparasitic agents. The
20analysis is illustrated by recent examples, with emphasis on the strategies
reported within the past 2 years.
Expert opinion: Virtual screening techniques are powerful tools commonly
used in drug discovery against parasitic diseases, which have provided new
opportunities for the identification of several novel compound classes with
25antiparasitic activity.
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1. Introduction
30Parasitic diseases are a major global cause of illness, morbidity, long-term disability
and death, with severe medical and psychological consequences for millions of men,
women and children [1]. Despite the high prevalence of parasitic diseases worldwide,
in most cases their treatment is inadequate, generating an urgent demand for new
antiparasitic drugs. However, in addition to the traditional challenges involved in
35the complex process of drug discovery and development, there is the hurdle of the
lack of investments in this field [2]. This situation is especially problematic in
de novo drug discovery, regarded as a high risk and costly process [3]. Therefore,
strategies that allow high quality hit identification rate as well as reduction in
drug discovery costs are extremely useful in this field.
40The biology of parasitic organisms has been continuously studied in detail, pro-
viding a solid base for the selection of relevant molecular targets for drug discovery.
Usually, hit and lead discovery begin with the application of either experimental or
in silico high-throughput screening (HTS) strategies [4]. In the particular case of par-
asitic diseases, broadly investigated in academia, virtual screening (VS) strategies
45play a major role in comparison to the traditional HTS. This is not only a conse-
quence of the lower costs and less infrastructure required, but also of the advantages
of this modern approach, which allows the identification of hits from a set of
privileged compounds.
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VS strategies, including the use of both ligand- and
50 structure-based methods, have been used in the search for
new inhibitors of relevant therapeutic targets related to para-
sitic diseases [3-10]. More recently, the combination of compu-
tational and experimental techniques has been explored as a
useful approach for the identification of high quality
55 hits [9,11-13]. This perspective paper outlines the progresses
and applications of in silico screening strategies for the discov-
ery of innovative chemotherapy agents for a variety of para-
sitic diseases, highlighting the challenges, limitations and
future perspectives in medicinal chemistry.
60
2. Ligand-based virtual screening
Ligand-based virtual screening (LBVS) strategies are powerful
methods that enable the discovery of bioactive compounds
based only on small-molecule information. LBVS essentially
focus on comparative molecular similarity analysis of
65 compounds with known and unknown activity. To this end,
a panel of known active and inactive compounds is used to
build robust models. Subsequently, the models are used to
select and sort the library molecules according to their likeli-
hood of binding to the target of interest. The VS process
70 can be based on several techniques, including molecular sim-
ilarity methods [12], pharmacophore models [14] or machine
learning methods [15]. These methods have been recently
reviewed elsewhere [15-17].
Challenges in the field include: i) the generation of models
75 able to identify ligands that significantly differ from the
original set of known actives and ii) the complexity to deal
with the presence of activity cliffs (i.e., substantial differences
in biological activity in very similar compounds) within struc-
ture--activity relationship (SAR) guided series [17]. However,
80recent approaches using LBVS highlight its power and versa-
tility for drug discovery being applied to the identification
of new classes of compounds that significantly differ from
the ligands used to derive the models or integrated with scaf-
fold hopping as a relevant tool to increase structural diversity
85and exploit unpatented chemical space [12,13,16].
In the field of parasitic diseases, recent successful examples
underscore the diversity of ligand-based strategies used to build
models capable of explaining and predicting the biological
activity within a particular series of antiparasitic compounds.
90Inhibitors of the enzymes cruzain and glyceraldehydes-
3-phosphate dehydrogenase (GAPDH) from Trypanosoma
cruzi, molecular targets for Chagas disease, have been investi-
gated by 2D and 3D quantitative structure-activity relation-
ship (QSAR) methods [7,18-20]. Additionally, studies based on
952D and 3D molecular similarity have been used to investigate
the biological activity underlying a series of benzimidazoles
against Trichomona vaginalis and Giardia intestinalis [21].
Regardless of the methods used in the VS, the strategy
consists in rationally selecting a set of high ranked molecules
100for experimental evaluation. The integration of VS and
QSAR strategies provides useful opportunities to capture
valuable information for compound selection (Figure 1). For
instance, in the design of new anticoccidial agents, QSAR
models were generated based on a set of 38 known drugs
105and 144 inactive compounds, randomly divided into training
and test sets. The best QSAR model was subsequently used in
a VS campaign to prioritize the compounds for experimental
testing. Ultimately, this combined approach guided the iden-
tification of compound 1 with substantial in vivo activity [22].
110Similarly, molecular fingerprints and QSAR models methods
have been used in the discovery of new classes of antitrypano-
somal (2) [6], antitrichomonal (3) [23] and antimalarial (4)
compounds (Figure 1) [5].
3. Structure-based virtual screening
115Advances in molecular biology have been essential for the iden-
tification and validation of biological targets of pharmaceutical
interest, while genomic and proteomic approaches have funda-
mentally contributed to the analysis of 3D macromolecular
organization and function. Concomitantly, improvements in
120physical techniques applied for structural determination and
molecular analyses, such as X-ray crystallography, NMR and
calorimetry, provided a deep understanding of both spatial
and energetic components underlying ligand--receptor binding
interactions [3]. Structure-based drug design methods incorpo-
125rate information from the target receptor; hence, these
knowledge-driven approaches require a good deal of infor-
mation about the target topology under investigation (e.g.,
X-ray crystal structure, NMR or robust homology
Article highlights.
. Ligand-based virtual screening (LBVS) and
structure-based virtual screening (SBVS) have been
proven to be cost-effective and efficient in generating
leads for further medicinal chemistry development,
without the complex infrastructure required to perform
experimental screenings (high-throughput
screening; HTS).
. The combination of LBVS and SBVS, as well as the
integration of SBVS and HTS, can be beneficial, as
indicated by the increasing number of hits identified.
. Approaches that integrate several screening techniques
significantly contribute to the prioritization of
compounds to be further investigated by more
sophisticated computational approaches or
experimental testing.
. Current challenges in the field consist in improving the
quality and performance of LBVS and SBVS, as well as
their integration with other modern drug discovery
strategies. To this end, partnerships with industries can
highly contribute to the success of the projects.
. The integration of LBVS and SBVS methods will continue
to enable and expand the application of these
approaches in the development of new chemotherapy
agents having promise of utility in clinical medicine.
This box summarizes key points contained in the article.
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modeling) [4]. In this context, public databases such as the
130 Protein Data Bank, Protein Data Bank in Europe and the
Structural Biology Knowledge Base are important data sources
to retrieve and analyze 3D structures of target proteins.
The wealth of structural information of attractive molecu-
lar targets and the evolution of computational methods have
135 prompted the development of a highly specialized screening
tool to identify promising compounds based on their comple-
mentarity to a specific binding site. This method, known as
structure-based virtual screening (SBVS), has made a remark-
able impact on the discovery of new drug candidates [3,4,10].
140 Owing to its intrinsic features, SBVS strongly depends on
the amount and quality of data available about the biological
system under investigation. Some general considerations
regarding the suitability of the molecular target for SBVS
studies include, but are not limited to: i) assessment of target
145 validation and druggability, incorporating features such as
pocket size, geometry, surface complexity and roughness,
and their complementarity in shape and polarity with respect
to a putative drug-like ligand; ii) analysis and selection of the
most relevant geometry of the target receptor, including mac-
150 romolecular flexibility for ligand binding; iii) assignment of
the correct protonation and tautomeric states, which is
required for the definition of crucial molecular properties
for ligand binding and affinity (e.g., local dielectric conditions
within the binding pocket can modulate pKa values of
155 functional groups which can easily turn a hydrogen acceptor
group into a donor or a charge-assisted hydrogen bond into
a neutral one) and iv) definition of structurally conserved
water molecules in the receptor binding site, which should
be taken into consideration for model development [4,10].
160The molecular recognition phenomenon relies on the
properties and features of a binding pocket, which are deter-
mined by the amino acids present in the binding cavity.
The spatial arrangement of the amino acids within the bind-
ing site specifies structural and physicochemical constraints
165that must be met by any putative ligand. Consequently, a
detailed analysis of the stereo-electronic properties of the
target binding pocket provides useful insights into relevant
ligand--receptor interactions. In this context, the use of the
structure-based pharmacophores has been successfully used
170in VS of drug-like databases [24]. The pharmacophore models
are used to select compounds with specific chemical and spa-
tial features that represent the essential interactions (e.g.,
hydrogen bonding, charge transfer, electrostatic, hydrophobic
interactions) between small-molecule ligands and the receptor
175binding pocket.
The use of structure-based pharmacophore models is espe-
cially attractive for drug discovery for parasitic diseases. Often,
the host and the parasite share common biochemical pathways
and the development of compounds which selectively bind to
180the parasite enzymes is required. In this context, pharmaco-
phore models are commonly used to explore the structural
differences between close homologs for the design of selective
inhibitors. The following examples provide a perspective of
the utility of the pharmacophore-based VS and its integration
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Figure 1. (A) Integrated approach for LBVS. (B) Antiparasitic compound classes discovered by LBVS.
LBVS: Ligand-based virtual screening.
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185 with other important experimental and computational
strategies in medicinal chemistry.
An example of the integration of pharmacophore models
and SBVS can be observed in the identification and optimiza-
tion of a novel class of inhibitors of Schistosoma mansoni
190 purine nucleoside phosphorylase (SmPNP), a key enzyme
involved in the purine salvage pathway of S. mansoni [25,26].
In this study, a 3D pharmacophore model was used to select
compounds with new structural scaffolds as competitive
inhibitors of SmPNP. By applying this filter, the initial set
195 containing > 300,000 molecules was reduced by 98% [8].
The resulting focused-library was sequentially docked into
the SmPNP binding site. Ultimately, this combined strategy
allowed the identification of three thioxothiazolidinones
derivatives (5 -- 7) as new reversible and competitive inhi-
200 bitors of SmPNP with IC50 values in the low micromolar
range (Figure 2). These inhibitors represent new potential
lead compounds for further development for the therapy
of schistosomiasis.
The impact of pharmacophore models on SBVS can also be
205 seen in the discovery of pyrazole-urea derivatives as potential
candidates for the treatment of malaria. In the apicomplexan
parasites, the actin--myosin A (MyoA) motor complex is a
key component in the gliding motility that is required for
the cell invasion process. A critical interaction occurs between
210 the myosin tail interacting protein (MTIP) and myosin A
(MyoA) facilitating the gliding action of the parasite [27].
The inhibition of this protein--protein interaction impairs
the gliding motility, thereby preventing the parasite to invade
the host cells. In order to identify compounds that target
215 the MTIP--MyoA interaction interface, a detailed structural
analysis of the MTIP--MyoA complex was performed. The
analysis supported the construction of a four-point struc-
ture-based pharmacophore model, which was subsequently
used to screen a library of nearly 300,000 compounds. Of
220 these, 40 compounds were selected and docked into the pro-
tein--protein interface. Finally, 15 compounds were acquired
and tested against Plasmodium falciparum cultures. The
most potent inhibitor (compound 8, EC50 = 145 nM) was
selected as lead compound for SAR studies (Figure 2). Several
225 derivatives with EC50 values in the nanomolar range were
identified as inhibitors of the parasite growth. The pharmaco-
phore model used in this work was designed to identify poten-
tial inhibitors that block the interaction between MTIP and
MyoA, consequently inhibiting the gliding motility of the
230 parasite. To explore the mechanism of inhibition in more
detail, the most potent inhibitors were tested for their ability
to reduce the parasite’s motility. The series of pyrazole-urea
derivatives (e.g., compound 9, EC50 = 385 nM) has shown
impairment in gliding motility, providing indirect evidence
235 that the compounds inhibit the MTIP--MyoA interaction
(Figure 2) [27].
The use of robust structural and biochemical information
for specific molecular systems has significantly contributed
to the discovery of antiparasitic agents bearing innovative
240scaffolds [3,10]. This assumption is corroborated by the identi-
fication of the structural determinants for ligand binding of
the enzyme pteridine reductase 1 from Trypanosoma brucei
(TbPTR1), an attractive biological target for the therapy of
human African trypanosomiasis (HAT) [28]. X-ray crystallo-
245graphic studies revealed extensive van der Waals and hydrogen
bonding interactions in the tertiary complexes incorporating
potent inhibitors (co-crystallized ligands), the cofactor
NADP+ and key amino acids of TbPTR1. Additionally, a
close inspection of the TbPTR1 binding pocket indicated
250important structural features for a fragment-based approach.
In light of this, a robust structure-based pharmacophore
model was generated and then used to screen a database of
250,000 compounds (Figure 2). It is worth noting that the
initial database was reduced by ~ 90% after the application
255of specialized fragment-like property filters (e.g., < 20 heavy
atoms, 1 -- 2 ring systems, ‡ 1 hydrogen-bond donor
group, < 4 rotatable bonds, and ClogP/ClogD < 3.5) [28].
The designed fragment library was docked into the
TbPTR1 binding site and the predicted orientation evaluated
260according to the pharmacophore model. The criteria for com-
pound selection were based on the quality of the hydrogen-
bond network and the shape complementarity between the
ligands and the binding site. This procedure resulted in the
identification of a series of 45 compounds that have their
265inhibitory activity evaluated against TbPTR1. The aminoben-
zimidazole derivative 10 (Ki = 10 µM) was selected as an
innovative scaffold for further SAR and crystallographic
studies (Figure 2). On the basis of the docked binding mode,
several analogs were synthesized and tested in order to evalu-
270ate the SARs underlying this series. The investigation led to
the development of compound 11 (Ki = 0.4 µM), which
exhibited binding affinity 25-fold higher than the parent
compound 10. Subsequently, the experimental binding
mode of compounds 10 and 11 was determined using X-ray
275crystallography, which allowed the identification of a large
hydrophobic pocket adjacent to the 7-position of the amino-
benzimidazole core. The molecular modification of 11 with
moieties suitable to fill the hydrophobic pocket led to the
discovery of compound 12 (Ki = 0.007 µM), a 7-phenyl-
280aminobenzimidazole derivative with binding affinity
improved by > 1400-fold in comparison to the initial VS
hit. Finally, the inhibitory activity of 12 was assessed against
T. brucei cultures, confirming that the compound was also
active in vitro (EC50 = 10 µM).
285
4. Integration of screening techniques
Several approaches using a combination of screening techni-
ques have recently been applied in the search for new
antiparasitic drugs, ranging from strategies that merge
computational techniques to cases in which virtual and
290experimental screenings are used sequentially or in parallel
to improve the hit rate. The power of these integrated
approaches is demonstrated by their enhanced performance,
In silico screening strategies for novel inhibitors of parasitic diseases
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Figure 2. SBVS strategies for the development of new leads for schistosomiasis (green), malaria (purple) and human African
trypanosomiasis (cyan). Pharmacophore models: H-donor groups (blue spheres); H-acceptor groups (red spheres); H-donor/
acceptor groups (magenta spheres) and hydrophobic groups (cyan spheres).
SBVS: Structure-based virtual screening.
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as demonstrated by the discovery of a large number of
biologically active compounds [9,13,29]. Fundamentally, these
295 methods differ in their speed and the necessary resources for
their application. Therefore, combined strategies make it
possible to use faster and cost-effective VS techniques as ratio-
nal filters for prioritizing compounds for further detailed
computational studies or experimental investigations.
300 A rich diversity of methods can be used in the integration
of LBVS and SBVS. For instance, the chemical space of the
hits identified by structure-based methods can be further
explored by LBVS (e.g., similarity searches). Alternatively,
LBVS may be used as a fast and reliable tool for the prioriti-
305 zation of compounds to be screened by SBVS. An example
can be seen in the discovery of new trypanothione reductase
inhibitors, a therapeutic relevant target to treat Chagas dis-
ease, HAT and leishmaniasis [12]. A library of > 8 million
compounds was screened by LBVS using the Molinspiration
310 VS ‘miscreen’, reducing the initial database to nearly
1300 compounds, which were then filtered based on absorp-
tion, distribution, metabolism and excretion (ADME)-Tox
properties, further decreasing the number of compounds
to ~ 600. The programs AUTODOCK and X-PLORE were
315 used to dock the molecules within the enzyme binding site,
leading to the selection of a final set of 19 compounds for bio-
chemical evaluation. Of these, 10 compounds were active
against T. cruzi trypanothione reductase, 6 of which with
IC50 < 50 µM (e.g., 13 -- 18, Figure 3) [12]. The high hit rates
320 obtained and the novelty of the compounds discovered under-
score the power of the application of LBVS as an efficient
filter to rationally prioritize compounds for SBVS.
VS techniques can be complemented by more sophisti-
cated, lower throughput computational methodologies, such
325 as molecular dynamics. The application of molecular dynam-
ics simulations to a privileged set of compounds selected
by VS approaches allows a more detailed evaluation of the
molecular events and interactions between the ligands and tar-
get protein [11,30]. For example, to search for inhibitors of the
330 T. cruzi GAPDH, ligand-based methods were used to select a
panel of 35 natural products to be tested in vitro against
the enzyme. Of these, seven molecules exhibited inhibitory
activity in the micromolar range. The three most potent com-
pounds were then docked into the binding site of the enzyme,
335 and the binding mode of the most potent compound was
evaluated by molecular dynamics. The simulation indicated
reasonable agreement with the SAR data, thereby providing
detailed information underlying the structural requirements
for ligand recognition and binding [11]. In another recent
340 example, steered molecular dynamics has been successfully
applied to identify true inhibitors from a set of active
and inactive polyhydroxylated flavones as inhibitors of the
P. falciparum a-hydroxyacyl-ACP dehydratase enzyme.
In this case, the only differences among the structurally
345 related compounds lay on the number and positioning of
the hydroxyl substituents around the flavone core.
Furthermore, a compound not included in the initial set was
correctly predicted as an inhibitor of the target enzyme [30].
These examples illustrate the applicability and efficiency
350of molecular dynamics as a complementary strategy for
LBVS and SBVS studies. However, it is worth mentioning
that the computational costs and the complexity of the
simulation methods may hinder its application as an actual
screening strategy.
355Improved performance for a significant number of targets
was observed by the application of LBVS and SBVS parallel
screening strategies as an in silico tool for drug design. In
this context, both approaches can be applied to the same
library of compounds and the final prioritization is based on
360a consensus scoring and comparison of the methods (e.g.,
the sum of the normalized scores or the combination of the
ranked compounds lists) [13]. Similarly, the benefits of com-
bining in silico and experimental HTS campaigns have
recently been evaluated [4,29]. Such an approach is exemplified
365by the screening of the same library of nearly 198,000 com-
pounds in parallel by both SBVS and HTS against the enzyme
cruzain, the major cysteine protease of T. cruzi. Given the
high number of hits obtained in the HTS (~ 1000 com-
pounds not easily identified as artifacts), the compounds
370were prioritized for confirmatory assays either based on their
VS ranking (e.g., among the top 1%) or on the most frequent
chemotypes among the hits. This combined approach led to
the discovery of five classes of reversible competitive inhibi-
tors, with Ki < 10 µM (e.g., compounds 19 -- 23). Out of these
375five classes, only one was identified by both approaches (com-
pound 21), whereas two classes were found exclusively by
HTS (compounds 22 and 23) and the other two were poorly
represented among HTS hits, which would have been ignored
for secondary assays if the VS results were not taken into
380account (compounds 19 -- 20) [9]. Accordingly, this study
emphasizes the complementarity between these techniques,
as each of the screening methods was able to identify ligands
that would be otherwise missed if a single screening strategy
was used (Figure 3).
385
5. Expert opinion
The application of in silico screening is a powerful strategy
that allows the identification of promising hits without the
complex infrastructure required to perform experimental
screenings (HTS). In the past few years, in silico screening
390techniques have been successfully applied in the discovery of
new classes of inhibitors for several key therapeutic targets
for parasitic diseases. Although LBVS and SBVS present
intrinsic technical limitations, there are many examples dem-
onstrating that these methods are cost-effective and efficient
395in generating leads for further medicinal chemistry develop-
ment. Interestingly, the classes of compounds identified usu-
ally differ considerably from the drugs already available.
Therefore, these approaches provide a source for innovation
and encouraging results have been obtained, providing
400starting points for lead optimization efforts. The combination
In silico screening strategies for novel inhibitors of parasitic diseases
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Figure 3. Integrated strategies for HTS. (A) Sequential application of LBVS and SBVS against trypanothione reductase (TryR).
(B) Selected examples of TryR inhibitors discovered by LBVS and SBVS; (C) Integration of SBVS and HTS in the discovery of new
classes of cruzain inhibitors.
HTS: High-throughput screening; LBVS: Ligand-based virtual screening; SBVS: Structure-based virtual screening.
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of LBVS and SBVS, as well as the integration of SBVS and
HTS, either sequential or in parallel can be beneficial as
indicated by the increasing number of hits identified. Alterna-
tively, the integrated approaches significantly contribute to
405 the prioritization of compounds to be further investigated
by more sophisticated computational approaches or experi-
mental testing. It is expected that SBVS methods will con-
tinue to gain strength with the steadily increasing number of
3D structures experimentally determined. At the same time,
410 new in silico strategies or the combination of the existing
ones are constantly being attempted and assessed. There is a
clear tendency of taking into account pharmacokinetic fea-
tures, as early as possible, in addition to the small-molecule
interactions related to affinity and biological activity, with
415 the objective of improving potency and efficacy, incorporat-
ing ADME properties in the selection of molecules with
drug (and lead)-like properties. The next challenges will
consist in improving the quality and performance of both
drug design methods, as well as their integration with other
420modern drug discovery strategies. We believe that this trend
is likely to increase the efficiency of delivering drug candidates
for parasitic diseases in the incoming years. To this end, part-
nerships with industries can be essential or, at least, highly rec-
ommended for boosting the success of the projects. In spite of
425the many scientific and technological challenges in this field,
what is clear is that the integration of LBVS and SBVS meth-
ods will continue to enable and expand the application of
these approaches in the development of new chemotherapy
agents having promise of utility in clinical medicine.
430
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